Cancer Discovery, the newest journal in the robust publication program of the American Association for Cancer Research, will debut at the AACR 102nd Annual Meeting 2011, held here from April 2-6.
The debut sample issue will feature research that enhances the classification of prostate cancer and proposes a possible new therapy, introduces potential new targets for lung cancer, and redefines immunotherapy in breast cancer.
Co-editors in Chief Lewis Cantley, Ph.D., director of the Beth Israel Deaconess Medical Center and professor of Systems Biology at Harvard Medical School, and Jose Baselga, M.D., Ph.D., associate director and chief of the division of hematology/oncology at the Massachusetts General Hospital, will host a press conference on these studies and discuss the implications of the new journal for the field. This press conference will be held on Sunday, April 3 at 1:00 p.m. ET in Room W313 of the Orange County Convention Center.
"Cancer Discovery is poised to make major contributions to the growing body of knowledge. These papers are examples of the practice-changing research we can expect from this esteemed journal," said Cantley.